Symptom burden of patients with moderate-to-severe atopic dermatitis

被引:10
|
作者
Egeberg, Alexander [1 ]
Anderson, Peter [2 ]
Piercy, James [3 ]
Massey, Lucy [4 ]
Cappelleri, Joseph C. [5 ]
Encinas, Gerardo A. [6 ]
Feeney, Claire [7 ]
Dibonaventura, Marco [8 ]
机构
[1] Univ Copenhagen, Bispebjerg Univ Hosp, Dept Dermatol, Nielsine Nielsens Vej 9, DK-2400 Copenhagen, Denmark
[2] Adelphi Mill, Adelphi Real World, Brand & Sci Commun, Macclesfield SK10 5JB, Cheshire, England
[3] Adelphi Mill, Hlth Econ & Outcomes Res, Adelphi Real World, Macclesfield SK10 5JB, Cheshire, England
[4] Adelphi Mill, Stat Anal, Adelphi Real World, Macclesfield SK10 5JB, Cheshire, England
[5] Pfizer Inc, Dept Stat, 445 Eastern Point Rd, Groton, CT 06340 USA
[6] Pfizer Inc, Emerging Markets, 3930 Braemar Pl, N Vancouver, BC V7N 4M8, Canada
[7] Pfizer Ltd, Global TA Med Affairs, Dorking Rd,Walton Hill, Tadworth KT20 7NS, Surrey, England
[8] Pfizer Inc, Hlth Econ & Outcomes Res, 235 East 42nd St, New York, NY 10017 USA
关键词
atopic dermatitis; burden; health-related quality-of-life; HEALTH;
D O I
10.1684/ejd.2021.4166
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease associated with intense and persistent pruritus. Objectives: To examine associations between AD symptoms and health-related quality of life (HRQoL) in adults (aged >= 18 years) with moderate-to-severe AD. Materials & Methods: Patient chart and survey data from physicians within Europe were derived from the Adelphi AD Disease Specific Programme (Q3 2019-Q2 2020). HRQoL measures included Euro-Qol 5-dimension, 3-level, questionnaire; Dermatology Life Quality Index; and Work Productivity and Activity Impairment-Atopic Dermatitis questionnaire. Data were evaluated using descriptive statistics and generalized linear models. Results: Of 631 patients, 90.1%, 49.3%, 18.5% and 17.7% reported pruritus, sleep disruption, anxiety and depression, respectively. Adjusted analyses indicated an increased frequency of symptoms associated with worse HRQoL and greater work/activity impairments, particularly for patients with pruritus and sleep disruption. Conclusion: Reductions in symptom frequency may have important implications for improving the overall health of patients with moderate-to-severe AD.
引用
收藏
页码:752 / 758
页数:7
相关论文
共 50 条
  • [1] Symptom burden of patients with moderate-to-severe atopic dermatitis
    Alexander Egeberg
    Peter Anderson
    James Piercy
    Lucy Massey
    Joseph C. Cappelleri
    Gerardo A. Encinas
    Claire Feeney
    Marco Dibonaventura
    European Journal of Dermatology, 2021, 31 : 752 - 758
  • [2] Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
    Smith, Brandon I.
    Engel, Priya
    Wu, Jashin
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (24): : 2299 - 2300
  • [3] Clinical burden and work productivity impairment in moderate-to-severe atopic dermatitis patients in the United States
    Feldman, Steven R.
    Guerin, Annie
    Gauthier-Loiselle, Marjolaine
    Claxton, Ami J.
    Hazra, Nisha C.
    Meng, Yan
    Gallant, Kirsten
    Balu, Sanjeev
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II45 - II46
  • [4] Baricitinib for the treatment of pediatric patients with moderate-to-severe atopic dermatitis
    Paller, Amy
    Chu, Chia-Yu
    Yang, Chin-Yi
    Janes, Jonathan
    Prakash, Apurva
    Rueda, Maria Jose
    Stanley, Sarah
    Wu, Wen-Shuo
    Zhang, Xin
    Eichenfield, Lawrence
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB108 - AB108
  • [5] Disease severity and needs of patients with moderate-to-severe Atopic Dermatitis
    Siegels, D.
    Abraham, S.
    Heinrich, L.
    Birkner, T.
    Haufe, E.
    Weidinger, S.
    Werfel, T.
    Schmitt, J.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (12) : S197 - S197
  • [6] Apremilast Use for Moderate-to-Severe Atopic Dermatitis in Pediatric Patients
    Saporito, Rachael C.
    Cohen, David J.
    CASE REPORTS IN DERMATOLOGY, 2016, 8 (02): : 179 - 184
  • [7] Dupilumab in the treatment of moderate-to-severe atopic dermatitis
    Kraft, Magdalena
    Worm, Margitta
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (04) : 301 - 310
  • [8] Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis
    James E. Frampton
    Hannah A. Blair
    American Journal of Clinical Dermatology, 2018, 19 : 617 - 624
  • [9] Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis
    Frampton, James E.
    Blair, Hannah A.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2018, 19 (04) : 617 - 624
  • [10] Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis
    Villegas, Susan C.
    Dima, Lorena
    AMERICAN JOURNAL OF THERAPEUTICS, 2023, 30 (02) : E117 - E125